MPLT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025
Revenue
0
0
0
Cost of Revenue
0
0
0
Gross Profit
0
0
0
Operating Expenses
63.5M
-1.5%
64.5M
-22.6%
83.4M
R&D
53.4M
-0.5%
53.7M
-16.9%
64.6M
SG&A
10.1M
-6.5%
10.8M
-42.3%
18.8M
Operating Income
-63548000
+1.5%
-64503000
+22.6%
-83377000
EBITDA
-63401000
+1.5%
-64341000
+22.7%
-83237000
Net Income
-60192000
+0.8%
-60668000
+23.7%
-79548000
EPS (Basic)
$-1.32
+1.5%
$-1.34
+45.3%
$-2.45
EPS (Diluted)
$-1.32
+1.5%
$-1.34
+45.3%
$-2.45
Shares (Diluted)
45.4M
+0.3%
45.3M
+39.7%
32.4M
MapLight Therapeutics (MPLT) โ€” Financials